In a statement, the AIM-listed company said its broker, Turner Pope will issue, in aggregate, 91,253,530 new ordinary shares at 1.5p each, utilising all of the funding headroom currently available to the group without the need for further shareholder approval.
The group noted that directors Gerard Brandon, Camillus Glover and Fionán Murray - respectively, the company’s CEO, COO and sales director - have agreed to subscribe equally for, in aggregate, 3,253,531 new ordinary shares under the subscription.
Integumen said it is intending to double the size of its Labskin laboratory in York, currently at 3,162 square feet, which could provide an estimated 10-fold increase on 2019 turnover capacity.
The company also gave a brief trading update, noting that in the nine months ended 30 September 2019, it achieved turnover of £0.591mln, compared with £0.116mln in the comparative period in 2018, with gross margins of 78%, and posted an EBITDA loss of £0.668mln, a reduction of £0.134mln on the comparative period in 2018.
It pointed out that overheads for the nine-month period ended 30 September 2019 totalled £1.129mln, an increase of £0.24mln, reflecting the incorporation of Rinocloud operating costs since 2 May 2019 and the appointment of additional laboratory and management staff.
As at 30 September 2019, the group said, it had cash balances of £0.477mln.
Brandon, Integumen’s chief executive Officer, commented: "Even with cash in the bank, a very low-geared (8%) balance sheet and profitability in sight, it is necessary for the company to provide verifiable assurances during a client's due diligence process that its cash buffer is strong throughout the duration of each client's engagement with the company.”
He added: “The monies raised will provide this buffer and enable this continued rapid growth of sales to many leading global skincare companies through the expansion of both facilities and employees.
“With the visibility we have of sales into next year, 2020 is already looking to be a good year for Integumen."
In early morning trade, shares in Integumen were 3.5% lower at 1.505p.